DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneSMAvoice.com | ||
If you'd like to unsubscribe and stop receiving these emails click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
Biogen Announces New Updates Across Its SMA Research Program at 2022 MDA Conference
Biogen Inc. announced new data and updates from its SPINRAZA® (nusinersen) and spinal muscular atrophy (SMA) research program aimed at improving clinical outcomes for people impacted by the disease, including the ASCEND, RESPOND and NURTURE studies. These updates were presented at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 13-16, 2022).
First Patient Treated in Phase 3b ASCEND Study
The ASCEND study is currently enrolling with the first patient treated in Q1 2022. At the conference, Biogen presented the design of the open-label, global Phase 3b study to evaluate the potential benefit of investigational higher dose nusinersen in later-onset, non-ambulatory SMA patients previously treated with Evrysdi® (risdiplam).
“As the SMA community gains more experience with available therapies, we are gleaning new insights about how these treatments can enhance the lives of individuals impacted by SMA. However, unmet needs still remain for the community,” said Basil Darras, M.D., Professor of Neurology at Harvard Medical School and Director of the Neuromuscular Center and Spinal Muscular Atrophy Program at Boston Children’s Hospital. “The ASCEND study seeks to generate data that have the potential to inform decisions regarding treatment for our patients with later-onset SMA.”
Related Content
-
EducationGene Replacement Therapy With Onasemnogene Abeparvovec in Children With Spinal Muscular Atrophy Aged 24 Months or Yo...Given the novelty of gene replacement th...
-
EducationCell-Penetrating Peptide-Conjugated Morpholino Rescues SMA in a Symptomatic Preclinical ModelSpinal muscular atrophy (SMA) is a motor...
-
News & MeetingsSafety and Efficacy Data Published for Novel Nusinersen Drug Delivery Method for Spinal Muscular Atrophy PatientsA recently published paper details the s...
-
EducationA Caregiver’s Guide to ZolgensmaIndication ZOLGENSMA® (onasemnogene abe...
-
EducationPatient and Caregiver Treatment Preferences in Type 2 and Non-Ambulatory Type 3 Spinal Muscular Atrophy: A Discrete ...Background: Spinal muscular atrophy (SMA...
-
Videos & VisualsLunch & Learn: Gene Therapy for SMAhttps://www.youtube.com/watch?v=YFEMR1ZH...
-
EducationRisdiplam for the Use of Spinal Muscular AtrophySpinal muscular atrophy (SMA) is one of ...
send a message
Reset password
password changed successfully!
please log in with your email address and new password.
your activation key expired
this confirmation key has expired. please try to log in again or resend confirmation email.
confirmation email sent
a confirmation email has been sent to your inbox. click the link in the email to activate your account.
can't find the email? be sure to check your spam folder.
password reset email sent
an email has been sent to you with a link to reset your password.
can't find the email? be sure to check your spam folder.
If you are a doctor or other qualified health care professional, you should not offer any medical advice or treatment on our Sites, nor should you allow the content of our Sites to substitute for your own medical judgment. Please thoroughly review the information provided on our Sites before deciding whether any of the products, services, or treatments therein are right for you or others.
your account is now activated!
Log in
This feature is only available to members.
you haven't confirmed your email address yet. resend confirmation email